101533442

03/03/2006 14:45

6102705090

GLAXOSMITHKLINE

PAGE 02/08

Docket No.: VB60410

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"DRYING PROCESS"

the specification of which (check one)

is attached hereto. **آ**]

was filed on 30 October 2003 [X]

and was amended on

Serial No. PCT/EP2003/012191 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Ap	plication(s)	Filing Date	Priority Claimed
Number 0225520.6 0225532.1 0225543.8 0317381.2 0317380.4 0317371.3	GB GB GB GB GB GB GB	01-Nov-2002 01-Nov-2002 01-Nov-2002 24-Jul-2003 24-Jul-2003 24-Jul-2003	YES YES YES YES YES YES YES

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number F	iling Date
----------------------	------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37,



REC'S PCT/PTO 0.3 MAR 2006 10153346

03/03/2006 14:45

6102705090

GLAXOSMITHKLINE

PAGE 03/08

Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status	
Serial 140.			
Disease all garres	nondence to the address ass	ociated with Customer Num	iber 20462.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor:

Inventor's Signature:

Date: 22 April

Residence:

Rixensart, Belgium

Citizenship:

Belgian

13 G.X

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

Resid PCT/PTO 0 3 MAR 2006 10/533462

03/03/2006 14:45

6102705090

GLAXOSMITHKLINE

PAGE 04/08

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required	to respons		PCT/EP2003/012191
Officer the Labor work		ition Number	30 October 2003
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS		Daté	Yves MAYERESSE
		amed Inventor	DRYING PROCESS
			DRYINGFROELSS
		it	
INDICATION FORM	Frami	ner Name	
·	Attorn	ey Docket Number	VB60410
I hereby appoint: Practitioners associated with the Customer Numbers. 20462			
☐ Practitioner(s) named below:			Registration Number
Name			
As my/our attorney(s) or agent(s) to prosecute the appli	- sien ide	atified above, and to t	ransact all business in the
As any low attorney(s) or agent(s) to prosecute the appli	Canon idei	illifica above,	
United States Fuert	r	avoridentified applica	tion to:
Please recognize or change the correspondence address	S for me au	Jimper.	
Please recognize or change the correspondence address The address associated with the above-mentioned	Customer .	102.100	j.
Or	20462	}	
Or The address associated with Customer Number	20402		
Or Firm or Individual Name:			
Plan of materials reserve			
Address:			Zip:
Address:		State:	
City:			
Country:		Fax:	
Telephone:			
I am the:			
Applicant/Inventor: Assignee or record of the entire interest. Sec 37 CFR 3.71. Assignee or record of the entire interest. (Form PTO/SB/96)			
Ct-tement under 37 CFR 3. (5(0))s cholosts. \ = A seignee of Record			
SIGNATURE U 9 MAT 2003			
Signature: Us rate And Milliam PATTON Telephone: +44 20 8047 4401			
Name: Marcus Jonuman William DALTON Telephone: +44 20 804 7 4401 Name: Marcus Jonuman Authorised Official, GlaxoSmithKline Biologicals s.a			
Title and Company: Attorney and Authority of the entire interest or their representatives			
NOTE: Signatures of all the inventors or assignees of permitted see below*.			
NOTE: Signatures of all the inventors of assignees of records. Submit multiple forms if more than one signature is required, see below*.			
Submit multiple forms if more than one signature is required. Total of: forms are submitted. This collection of information is required by 37 CFR 1.31 and 1.33. The information is required by 35 U.S.C. 122 This collection of information by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122			
This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain of retaining the collection of information is required by 37 CFR 1.31 and 1.33. The information is required by 35 U.S.C. 122 by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 by the public which is to file (and by the USPTO). The process of the information is required to obtain or retained by 37 U.S.C. 122 by the public which is to file (and by the USPTO). The process of the information is required to obtain or retained by 35 U.S.C. 122 by the public which is to file (and by the USPTO). The process of the information is required to obtain or retained by 35 U.S.C. 122 by the public which is to file (and by the USPTO). The process of the information is required to obtain or required to obtain the information is required to obtain the			
by the public which is to file (and by the USPTO to	process) a	s to complete, includi	ng gathering, preparing, and submitting
and 37 CRF 1.14. This collection is essential to tak	on Hiter on	depending upon the	individual case. Any comments on the

the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

REGIS PCLIPTO .0 3 MAR 2006 10/533442

03/03/2006 14:45

6102705090

GLAXOSMITHKLINE

PAGE 05/08

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CRF 3.73(b) Applicant/Patent Owner: GlaxoSmithKline Biologicals s.a. International Application No./Patent No.: PCT/EP2003/012191 Filed/Issue Date: 30 October 2003 Entitled: DRYING PROCESS GlaxoSmithKline Biologicals s.a., a corporation, states that it is: 1. Et the assignee of the entire right, title, and interest; or 2. an assignee of less than the entire right, title and interest. The extent (by percent age) of its ownership interest is% in the patent application/patent identified above. The assignment was
1. ☐ the assignee of the entire right, title and interest. 2. ☐ an assignee of less than the entire right, title and interest. The extent (by percent
1. If the assignee of the entire right, title and interest. 2. In an assignee of less than the entire right, title and interest. The extent (by percent application/patent identified above)
2. an assigned of less than the characteristic and the characteristic and assigned of less than the characteristic and the c
The extent (by percent
- Site amporehin interest IS 70 th the pattern II
age) of its ownership index of either.
age) of its ownership interest is% in the patent application/patent identified above. The assignment was by virtue of either; A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office at Reel, Frame, or for which recorded in the United States Patent and Trademark Office States Patent and Trademark Office States Patent All
A. [] All assignment of the United States Patent and Trademark Office at Nect
copy thereof is attached.
OR B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignce
B [] A chain of title from the inventor(s), of the patent appreciates
B. [] A chain of title from the invented by as shown below: 1. From: The document was recorded in the United States Patent and Trademark Office at or for which a copy thereof is attached.
1. From:it is the United States Patent and Trademark Office at
The document was recorded in the Officer batter of for which a copy thereof is attached.
2. From: The document was recorded in the United States Patent and Trademark Office at The document was recorded in the United States Patent and Trademark Office at The document was recorded in the United States Patent and Trademark Office at
The designant was recultuous was a series a construction to audonous
Recl Frame To:
Recl
The document was recorded in the United States , or for which a copy thereof is attached.
Reel field are listed on a supplemental sheet.
[] Additional documents in the chain of title are attached.
[X] Copies of assignments or other documents in the chain of title are attached. [X] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment [NOTE: A separate copy (i.e., a true copy of the original assignment is to be recorded in the records of the USPTO. Division in accordance with 37 CRF Part 3, if the assignment is to be recorded in the records of the USPTO.
all private on hehalf of the assignee.
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. 0 9 MAY 2005
Macus 1 Mer Date
+44 20 8047 4401
Marcus Jonathan William DALTON Telephone Number
Printed or Typed Name
Attorney and Authorised Official
Title
The information is required to obtain or retain a benefit

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

03/03/2006 14:45

6102705090

GLAXOSMITHKLINE

PAGE 06/08

Docket No.: VB60410

ASSIGNMENT

WHEREAS I/We, Yves MAYERESSE of Rixensart, Belgium have made an invention entitled:

DRYING PROCESS

April 22, 2005	I/we executed an application for Letters
for which on of America:	•
Patent of the United States of America;	

NOW, THEREFORE, in return for valuable consideration paid to me/us by GlaxoSmithKline Biologicals s.a. of Rue de l'Institut 89, B-1330 Rixensart, Belgium (hereinafter "ASSIGNEE"), the receipt of which is hereby acknowledged and intending to be legally bound, I/we do hereby assign unto the said invention, ASSIGNEE, its successors and assigns, the entire right, title and interest in and to the said invention, said executed application, any division, continuation and continuation-in-part of said application and reissue applications, and all Letters Patents of the United States of America to be obtained therefor,

I/we hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

In addition I/we agree to provide ASSIGNEE upon its request with all pertinent facts and documents relating to said invention, and said Letters Patent as may be known and accessible to me/us, and to testify as to the same in any interference or litigation related thereto, and to execute further instruments (including divisional, continuation, continuation-in-part or reissue applications, affidavits or other instruments) required to apply for, obtain, maintain and enforce said application and said Letters Patent which may be necessary; this agreement to be binding upon my/our heirs, executors and administrators.

Inventor 1
Yves MAYERESSE

Date: 22 April 2005